SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

11/12/24 9:12:40 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TARS alert in real time by email

SC 13G 1 TARS093024.txt TARS09302024 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of Issuer: Tarsus Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 87650L103 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 87650L103 1. Name of Reporting Person: Jennison Associates LLC S.S. or I.R.S. Identification No. of Above Person: IRS Identification #52-2069785 (formerly 13-2631108) 2. Check the Appropriate Box if a Member of a Group: Not Applicable 3. SEC Use Only 4. Citizenship or Place of Organization: Delaware Number of Shares Beneficially Owned By Each Reporting Person With: 5. Sole Voting Power: 2,178,580 shares 6. Shared Voting Power: 0 shares 7. Sole Dispositive Power: 0 shares 8. Shared Dispositive Power: 2,178,580 shares 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 2,178,580 shares 10. Check Box if the Aggregate Amount in Row 9 Excludes Certain Shares: ( ) 11. Percent of Class Represented by Amount in Row 9: 5.7% 12. Type of Reporting Person*: IA Item 1(a) Name of Issuer: Tarsus Pharmaceuticals, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 15440 LAGUNA CANYON ROAD IRVINE, CA 92618 Item 2(a) Name of Person Filing: Jennison Associates LLC Item 2(b) Address of Principal Business Office or Residence: 466 Lexington Avenue New York, NY 10017 Item 2(c) Citizenship: Delaware Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 87650L103 Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), or (c) check whether the person filing is a: (a) ( ) Broker or Dealer registered under Section 15 of the Act (b) ( ) Bank as defined in Section 3(a) (6) of the Act (c) ( ) Insurance Company as defined in Section 3(a) (19) of the Act (d) ( ) Investment Company registered under Section 8 of the Investment Company Act (e) (X) Investment Adviser in accordance with Section 240.13d-1(b) (1) (ii) (E) (f) ( ) Employee Benefit Plan, Pension Fund which is subject to the provision of the Employee Retirement Income Security Act of 1974 or Endowment Fund in accordance with Section 240.13d-1(b) (ii) (F) (g) ( ) Parent Holding Company or control person, in accordance with Section 240.13(b) (ii) (G) (h) ( ) A savings association as defined by Section 3(b) of the Federal Deposit Insurance Act (i)( ) A church plan that is excluded from the definition of an investment company under Section 3(c) (4) of the Investment Company Act of 1940. (j)( ) Group, in accordance with Section 240.13d-1(b) (1) (ii) (J). If this statement is filed pursuant to Section 240.13d-1(c), check this box. ( ) Item 4 Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 2,178,580 shares (b) Percent of Class: 5.7% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 2,178,580 shares (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 2,178,580 shares Jennison Associates LLC ("Jennison") furnishes investment advice to several investment companies, insurance separate accounts, and institutional clients ("Managed Portfolios"). As a result of its role as investment adviser of the Managed Portfolios, Jennison may be deemed to be the beneficial owner of the shares of the Issuer's Common Stock held by such Managed Portfolios. Prudential Financial, Inc. ("Prudential") indirectly owns 100% of equity interests of Jennison. As a result, Prudential may be deemed to have the power to exercise or to direct the exercise of such voting and/or dispositive power that Jennison may have with respect to the Issuer's Common Stock held by the Managed Portfolios. Jennison does not file jointly with Prudential, as such, shares of the Issuer's Common Stock reported on Jennison's 13G may be included in the shares reported on the 13G filed by Prudential. These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Jennison is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the securities, check the following ( ). Item 6 Ownership of More than Five Percent on Behalf of Another Person: Our clients have the right to receive or the power to direct the receipt of dividends or the profits from the sale of such securities. No one client owns more than 5% of such security class. Item 7 Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company: Not Applicable Item 8 Identification and Classification of Members of the Group: Not Applicable Item 9 Notice of Dissolution of Group: Not Applicable Item 10 Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are in held the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the correct information set forth in this statement is true, complete and correct. November 12, 2024 /s/ Beata Markowicz Beata Markowicz Vice President

Get the next $TARS alert in real time by email

Recent Analyst Ratings for

$TARS

Date	Price Target	Rating	Analyst
6/2/2025	$75.00	Outperform	Oppenheimer
5/27/2025	$72.00	Buy	H.C. Wainwright
11/20/2023	$19.00	Neutral	Goldman
7/18/2023	$44.00	Outperform	William Blair
5/18/2023		Buy	Guggenheim
8/1/2022	$40.00	Overweight	Barclays
12/21/2021	$40.00	Buy	HC Wainwright & Co.
11/23/2021	$55.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for
$TARS

$TARS
SEC Filings

Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

$TARS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

$TARS
Press Releases

Fastest customizable press release news feed in the world

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

$TARS
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

$TARS
Leadership Updates

Live Leadership Updates

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $TARS

$TARS SEC Filings

Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

$TARS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

$TARS Press Releases

Fastest customizable press release news feed in the world

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

$TARS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

$TARS Leadership Updates

Live Leadership Updates

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

Recent Analyst Ratings for
$TARS

$TARS
SEC Filings

$TARS
Insider Purchases

$TARS
Press Releases

$TARS
FDA approvals

$TARS
Leadership Updates